Racial and Genetic Biomarkers of Response in Tissue Samples From Patients With Endometrial Cancer
Recruitment status was Not yet recruiting
RATIONALE: Studying samples of tissue from patients with cancer in the laboratory may help doctors learn more about changes that occur in DNA and identify biomarkers related to cancer. DNA analysis of tumor tissue may also help doctors predict how well patients will respond to treatment.
PURPOSE: This research study is studying racial and genetic biomarkers of response in tissue samples from patients with endometrial cancer.
Genetic: gene expression analysis
Other: laboratory biomarker analysis
Other: medical chart review
Other: study of socioeconomic and demographic variables
|Official Title:||The Relationship of Racial Genetic Admixture With Endometrial Cancer Outcomes|
- Proportion of genetic background that is of African-American descent [ Designated as safety issue: No ]
- Progression-free survival and overall survival [ Designated as safety issue: No ]
- Clinicopathologic and demographic characteristics [ Designated as safety issue: No ]
|Study Start Date:||October 2010|
|Estimated Primary Completion Date:||November 2010 (Final data collection date for primary outcome measure)|
- To identify racial categorization as the proportion of genetic background of African-American or European-American women with endometrioid endometrial cancer (EEC).
- To evaluate the association of racial genetic admixture with clinicopathologic variables and outcomes.
- To compare the concordance between racial genetic admixture and self-designated race categorization.
OUTLINE: This is a multicenter study. Patients are stratified by race (African-American vs European-American) and disease stage (I vs II vs III vs IV).
DNA from archived frozen normal tissue samples are genotyped for the ancestry informative markers. Clinicopathological and demographic characteristics associated with each sample are also collected.
|Principal Investigator:||Rodney P. Rocconi, MD||University of South Alabama Mitchell Cancer Institute|